EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

ALZ ‐801 prevents amyloid β‐protein assembly and reduces cytotoxicity: A preclinical experimental study

Daiki Muramatsu iD, Takahiro Watanabe-Nakayama iD, Mayumi Tsuji iD, Kenichi Umeda iD, Sadao Hikishima iD, Hiroto Nakano iD, Yasuhiro Sakashita iD, Tokuhei Ikeda iD, Hiroki Konno iD, Noriyuki Kodera iD, Toshio Ando iD, Moeko Noguchi-Shinohara iD und 1 weitere

The FASEB Journal · 2025

DOI: 10.1096/fj.202402622r ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, 2025. Verfasst von Daiki Muramatsu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan. Hauptthemen laut MEDLINE: Amyloid beta-Peptides, Peptide Fragments. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: MEXT | Japan Society for the Promotion of Science (JSPS), Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD) is the most prevalent age‐related neurodegenerative disorder, mainly characterized by amyloid β (Aβ) accumulation in the brain. Numerous new agents are currently undergoing clinical trials as disease‐modifying therapies (DMTs) targeting Aβ. ALZ‐801 is a promising candidate DMT for AD, with a phase 3 trial of ALZ‐801 ongoing specifically for apolipoprotein E (APOE) ε4 homozygous patients with early‐stage AD. This study aimed to examine the effects of ALZ‐801 on Aβ assembly and explore its toxicological profile. Thioflavin T (ThT) assays and two imaging modalities—transmission electron microscopy (TEM) and high‐speed atomic force microscopy (HS‐AFM)—were used to evaluate ALZ‐801's effects on Aβ assembly. To assess the effect of ALZ‐801 on Aβ 42 ‐induced cytotoxicity, 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT) assays and lactate dehydrogenase (LDH) assays were performed. ThT assays revealed increased lag time and decreased fluorescence in the presence of ALZ‐801, confirming inhibition of Aβ 42 fibril formation, as confirmed by TEM. Real‐time observation using HS‐AFM revealed that ALZ‐801 inhibited the formation of Aβ 42 fibril from low‐molecular‐weight (LMW)‐Aβ 42 in the presence of Aβ 42 seeds. HS‐AFM also revealed that globular aggregates from LMW‐Aβ 42 were significantly larger with ALZ‐801, with few fibrils noted. MTT and LDH assays indicated that ALZ‐801 prevented LMW‐Aβ 42 ‐induced cytotoxicity but did not reduce cytotoxicity induced by high‐molecular‐weight‐Aβ 42 . ALZ‐801 can inhibit Aβ 42 aggregation by preventing both nucleus formation and fibril elongation, while promoting large globular oligomer formation, and can significantly reduce LMW‐Aβ 42 ‐induced cytotoxicity. These findings underscore the potential of ALZ‐801 as an effective DMT for APOE ε4 homozygous patients with AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid beta-PeptidesPeptide FragmentsHumansAnimalsAlzheimer DiseaseMicroscopy, Atomic ForceCell SurvivalRats

Stichwörter der Autor:innen

ALZ‐801Alzheimer diseaseamyloid beta‐peptidesapolipoproteins Eatomic force, microscopyprotein aggregates

Substanzen

Amyloid beta-PeptidesPeptide Fragmentsamyloid beta-protein (1-42)

Autor:innen und Institutionen

  • Department of Neurology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.
  • World Premier International Research Center Initiative (WPI)-Nano Life Science Institute, Kanazawa University, Kanazawa, Japan.
  • Pharmacological Research Center, Showa University, Tokyo, Japan.

ORCID-Profile: Daiki Muramatsu, Takahiro Watanabe-Nakayama, Mayumi Tsuji, Kenichi Umeda, Sadao Hikishima, Hiroto Nakano, Yasuhiro Sakashita, Tokuhei Ikeda, Hiroki Konno, Noriyuki Kodera, Toshio Ando, Moeko Noguchi-Shinohara, Kenjiro Ono

Förderung

  • MEXT | Japan Society for the Promotion of Science (JSPS)
  • Japan Society for the Promotion of Science

Zitieren

APA

Muramatsu, D., Watanabe-Nakayama, T., Tsuji, M., Umeda, K., Hikishima, S., Nakano, H., Sakashita, Y., Ikeda, T., Konno, H., Kodera, N., Ando, T., Noguchi-Shinohara, M., & Ono, K. (2025). ALZ ‐801 prevents amyloid β‐protein assembly and reduces cytotoxicity: A preclinical experimental study. The FASEB Journal. https://doi.org/10.1096/fj.202402622r

Vancouver

Muramatsu D, Watanabe-Nakayama T, Tsuji M, Umeda K, Hikishima S, Nakano H, et al. ALZ ‐801 prevents amyloid β‐protein assembly and reduces cytotoxicity: A preclinical experimental study. The FASEB Journal. 2025. doi:10.1096/fj.202402622r

BibTeX
@article{Muramatsu2025,
  author = {Muramatsu, Daiki and Watanabe-Nakayama, Takahiro and Tsuji, Mayumi and Umeda, Kenichi and Hikishima, Sadao and Nakano, Hiroto and Sakashita, Yasuhiro and Ikeda, Tokuhei and Konno, Hiroki and Kodera, Noriyuki and Ando, Toshio and Noguchi-Shinohara, Moeko and Ono, Kenjiro},
  title = {ALZ ‐801 prevents amyloid β‐protein assembly and reduces cytotoxicity: A preclinical experimental study},
  journal = {The FASEB Journal},
  year = {2025},
  doi = {10.1096/fj.202402622r}
}
Kostenlos starten →